Literature DB >> 22202152

Targeted alpha therapy with 213Bi.

Alfred Morgenstern1, Frank Bruchertseifer, Christos Apostolidis.   

Abstract

The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.

Mesh：

Substances：

Year:  2011        PMID： 22202152     DOI： 10.2174/1874471011104040295

Source DB:  PubMed          Journal:  Curr Radiopharm        ISSN： 1874-4710


  12 in total

1.  Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.

Authors:  Julia Fazel; Silvia Rötzer; Christof Seidl; Benedikt Feuerecker; Michael Autenrieth; Gregor Weirich; Frank Bruchertseifer; Alfred Morgenstern; Reingard Senekowitsch-Schmidtke
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

Review 2.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Authors:  Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

3.  Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest.

Authors:  Mario Vallon; Christof Seidl; Birgit Blechert; Zhoulei Li; Klaus-Peter Gilbertz; Anja Baumgart; Michaela Aichler; Annette Feuchtinger; Florian C Gaertner; Frank Bruchertseifer; Alfred Morgenstern; Axel K Walch; Reingard Senekowitsch-Schmidtke; Markus Essler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-08       Impact factor: 9.236

4.  Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.

Authors:  Hossein Jadvar
Journal:  Cancer Biother Radiopharm       Date:  2020-03-23       Impact factor: 3.099

Review 5.  Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Authors:  Rubel Chakravarty; Cerise M Siamof; Ashutosh Dash; Weibo Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-08-20

6.  α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.

Authors:  Katharina Teiluf; Christof Seidl; Birgit Blechert; Florian C Gaertner; Klaus-Peter Gilbertz; Vanesa Fernandez; Florian Bassermann; Jan Endell; Rainer Boxhammer; Stephane Leclair; Mario Vallon; Michaela Aichler; Annette Feuchtinger; Frank Bruchertseifer; Alfred Morgenstern; Markus Essler
Journal:  Oncotarget       Date:  2015-03-10

7.  Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics.

Authors:  Jakub Šimeček; Petr Hermann; Christof Seidl; Frank Bruchertseifer; Alfred Morgenstern; Hans-Jürgen Wester; Johannes Notni
Journal:  EJNMMI Res       Date:  2018-08-08       Impact factor: 3.138

Review 8.  An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth.

Authors:  Alfred Morgenstern; Christos Apostolidis; Clemens Kratochwil; Mike Sathekge; Leszek Krolicki; Frank Bruchertseifer
Journal:  Curr Radiopharm       Date:  2018

9.  DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.

Authors:  Franziska Graf; Jörg Fahrer; Stephan Maus; Alfred Morgenstern; Frank Bruchertseifer; Senthil Venkatachalam; Christian Fottner; Matthias M Weber; Johannes Huelsenbeck; Mathias Schreckenberger; Bernd Kaina; Matthias Miederer
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

10.  Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate.

Authors:  Ho Sze Chan; Mark W Konijnenberg; Erik de Blois; Stuart Koelewijn; Richard P Baum; Alfred Morgenstern; Frank Bruchertseifer; Wouter A Breeman; Marion de Jong
Journal:  EJNMMI Res       Date:  2016-01-20       Impact factor: 3.138
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.